Needham & Company Starts BioTelemetry (BEAT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts BEAT Hot Sheet
Price: $0.48 -2.04%
Rating Summary:
7 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
7 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Needham & Company analyst Mike Matson initiates coverage on BioTelemetry (NASDAQ: BEAT) with a Buy rating and a price target of $52.00.
For an analyst ratings summary and ratings history on BioTelemetry click here. For more ratings news on BioTelemetry click here.
Shares of BioTelemetry closed at $36.67 yesterday.
You May Also Be Interested In
- BofA Securities Starts Penguin Solutions (PENG) at Buy
- Hovde Group Reinstates Pinnacle Financial Partners (PNFP) at Outperform
- Wolfe Research Starts Southwest Gas (SWX) at Peerperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
